CASSS Bioassays 2025 explores the development and control of potency assays across biologics, multispecific antibodies, antibody-drug conjugates and cell and gene therapies. The program links method design and characterization with regulatory strategy, reference standards, reagent management and ongoing assay performance. Scientific presentations, panel discussions and case studies examine challenges such as cytotoxicity testing, complex therapeutic mechanisms and new QC technologies. The meeting took place April 7–9, 2025, at the Gaithersburg Marriott Washingtonian Center in Maryland. It is intended for bioassay and analytical scientists, QC teams and CMC or regulatory professionals involved in biopharmaceutical development.
Learning Objectives
- Evaluate current perspectives, regulatory strategies, and technologies used in bioassay development.
- Analyze technical and regulatory details through high-quality case studies and scientific discussions.
- Formulate strategies for the development and standardization of methods used for bioassays.
- Implement specific bioassay strategies for multi-specific antibodies and antibody-drug conjugates.
- Assess emerging innovations and the development of new target cell lines to evaluate cytotoxicity.
Meeting Agenda
The following schedule includes the pre-conference short course, roundtables and other meeting activities. It provides context and does not establish that every item is included in the store package.
Monday, April 7, 2025
- WATCH NOW: Development of a New Class of Target Cell Lines to Evaluate Fc-Mediated Cytotoxicity
- Workshop Part I – Introduction to Bioassay Development: CMC Strategy and Practical Application
- Workshop Part II – Practical Applications for Method Design and Performance
Tuesday, April 8, 2025
- CASSS Welcome and Introductory Comments
- Keynote Presentation – The Special World of Bioassay: Key Learnings, Special Situations and Keys to Success
- Session I: Bioassays Foundations / Nuts and Bolts of Bioassays
- A Novel Cell-Based Potency Assay to Measure Cell/Cell Phagocytosis Induced by Antibody-Dependent Cellular Phagocytosis
- Afucosylation: Potency Evaluation Strategies
- Of Mice and (Wo)Men
- Session I: Panel Discussion
- Session II: Bioassay Strategies for Multi-Specific Antibodies
- Navigating the Complexities of Bi-Specifics: Leveraging Bioassays for Product Variant Characterization and Process Development
- Elranatamab: Bispecific mAb Bioassay Strategy from R&D to Commercialization
- Bridges Over Montgomery County: Revamping the Potency Specification Strategy for a Complex Modality
- Session II: Panel Discussion
- Poster Session
- Roundtable Session 1
- Let’s Brainstorm on Applications of AI for Bioassays
- Method Comparability and Method Bridging: Are They the Same Thing?
- Life Cycle Management of Reagents and Equipment
- Managing the Potency of Your Reference Standards
- How Are You Monitoring the Health of Your Bioassay Methods?
- Emerging Professionals Session
- Development of an in Vitro Bystander Killing Bioassay for ADCs
- Potency Control Strategy for Biotherapeutic Fusion Proteins
Wednesday, April 9, 2025
- Session III: Antibody Drug Conjugates
- Navigating Complexity: A Strategic Framework for Streamlining and Simplifying Antibody Drug Conjugates Development and Potency Assay Lifecycle Management
- Inducible Promoter Systems: Pioneering the Future of Bioassay Development for Enhanced Precision Control
- Use of High Content Imaging to Enable Cell-Based Potency Assay Development for ADCs
- Session III: Panel Discussion
- Roundtable Session 2
- Let’s Brainstorm on Applications of AI for Bioassays
- Method Comparability and Method Bridging: Are They the Same Thing?
- Life Cycle Management of Reagents and Equipment
- Managing the Potency of Your Reference Standards
- How Are You Monitoring the Health of Your Bioassay Methods?
- Poster Session
- Session IV: Emerging Technologies / Innovations in Bioassays
- MoA-Reflective Bioassays for Next-Gen QC Testing
- Development of Cell-based Potency Assays For a Novel Immunostimulatory Drug Conjugate
- Development of Fc-Receptor Bioassays to Unravel the Impact of Glycosylation
- Session IV: Panel Discussion
- Session V: Cell and Gene Therapy and More!
- Overcoming Challenges in Potency Bioassay Development: A Case Study on an Immunostimulatory Virus-Like Particle Investigational Drug
- Uniting for Success: Collaboration between Analytics, Research and Process Development for a CAR Potency Assurance Strategy
- Bridging Potency: Implementation of AAV Infectivity by Viral Entry Assay
- Session V: Panel Discussion
- Closing Remarks and Invitation to Bioassays 2026
Presenters Named in the Source
- Lena Knauber of AbbVie.
- Victoria Swiss of Bristol Myers Squibb.
- Yishi Liu of Genentech.
- Peter Richard of Pfizer.
- Dylan Weil of AstraZeneca.
- Larisa Toulokhonova of Merck.
- Madhumati Mukherjee of AstraZeneca.
- Nicole Shi of Eli Lilly.
- Andrea Parsons of Pfizer.
- Long Zheng of Bristol Myers Squibb.
- Ayumi Takayanagi of Chugai Pharmaceutical.
- Marshall Davis of Pfizer.
- Caterina Giorno and Daniel Markx of Boehringer Ingelheim.
- Cristinel Sandu of Regeneron.
- Sonia Connaughton of Sanofi.
- Ting He of Ultragenyx.
Supplied Recording List
-
CASSS Welcome and Introductory Comments
-
Keynote Presentation: The Special World of Bioassay Key Learnings Special Situations and Keys to Success
-
Session I: Bioassays Foundations Nuts and Bolts of Bioassays
-
Session I: Panel Discussion
-
Session II: Bioassay Strategies for Multi-Specific Antibodies
-
Session II: Panel Discussion
-
Session III: Antibody Drug Conjugates
-
Session III: Panel Discussion
-
Session IV: Emerging Technologies Innovations in Bioassays
-
Session IV: Panel Discussion
-
Session V: Panel Discussion
-
Development of a New Class of Target Cell Lines to Evaluate Fc-Mediated Cytotoxicity Presented by Svar Life Science
-
Lunch and Learn Vendor Showcase
-
Closing Remarks and Invitation to Bioassays 2026




